Fresh from Envision buy, GHO Capital acquires Canada’s Caprion Biosciences

London-based investment and advisory firm GHO Capital has acquired proteomics and immune monitoring services provider Caprion Biosciences for an undisclosed fee.

The Canadian company--a specialist lab services company which provides testing services to pharma and biotech companies for R&D--also runs its own diagnostic products targeting cancer, metabolic and infectious diseases.

The U.K.’s GHO Capital, which was only founded two years ago, gains in Caprion this expertise as well as a company with top-line growth of 22% over the past three years, and one that boasts of more than 50 pharma and biotech clients.

Mike Mortimer, partner at GHO Capital, said: “We believe that Caprion is a world-class business operating in a highly attractive, rapidly growing segment. As a well-respected service provider to the pharmaceutical industry, the management team has developed a scalable business model capable of delivering significant further growth, making this an exciting investment opportunity for our fund.

“With favourable market dynamics in immuno-oncology and proteomics, Caprion is well-positioned to expand its capabilities on a global scale.”

It’s been an acquisitive month for GHO Capital as at the beginning of July it announced its purchase of the science comms company Envision Pharma Group from its previous owner Halifax. Financial terms were here too not made public.

It may have only been around since 2014 but the firm is wasting no time and money in swiftly building up a diverse science portfolio.

Martin LeBlanc, president and CEO of Caprion, added: “We are delighted to enter into this exciting new partnership with GHO Capital.

“GHO Capital brings a unique combination and depth of relevant industry expertise, network and strategic insights that will undoubtedly help position Caprion to maintain the rapid growth trajectory we have achieved over the past seven years. We look forward to continuing to build on our leading immunology and proteomics services to further broaden our customer base and pursue our expansion both in Europe and internationally.”

- check out the release


Suggested Articles

Syneos Health is buying out midsized, late-stage focused contract research organization Synteract to help bolster its research services footprint.

Three big players in the trial data world are coming together to for real-world data studies.

A new report out by study management firm Greenphire says patient enrollment for global clinical trials “has returned to pre-COVID levels.”